NEW YORK CITY, NY / ACCESS Newswire / February 28, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential ...

In high-income countries, more than 80% of children diagnosed with cancer will survive. Yet in some low- and middle-income ...

As an enterprise engaged in the development, manufacturing and commercialization of specialty plasma-derived therapeutics, ...

Teva's stock is a speculative buy with potential upside if biosimilars succeed, but risks remain high due to debt and ...

The company is leaning on its subcutaneous technology to deliver long-acting options that could prevent patients from cycling through drugs.

The MSSG solidarity mechanism enables medicine sharing between EU states, with companies now required to report on drug ...